- Home
- MRKR
as 11-12-2025 10:01am EST
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.
Upcoming Earnings Alert:
Get ready for potential market movements as Marker Therapeutics Inc. MRKR prepares to release earnings report on 14 Nov 2025.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | HOUSTON |
| Market Cap: | 11.6M | IPO Year: | N/A |
| Target Price: | $10.25 | AVG Volume (30 days): | 156.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.81 - $5.95 | Next Earning Date: | 11-14-2025 |
| Revenue: | $5,388,071 | Revenue Growth: | 44.55% |
| Revenue Growth (this year): | -58.96% | Revenue Growth (next year): | 9.06% |
Latest Marker Therapeutics Inc. News
MRKR Breaking Stock News: Dive into MRKR Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 days ago
Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors
GlobeNewswire
5 months ago
Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma
GlobeNewswire
6 months ago
Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma
GlobeNewswire
6 months ago
Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies
Simply Wall St.
7 months ago
Marker Therapeutics Full Year 2024 Earnings: Misses Expectations
GlobeNewswire
7 months ago
Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference
GlobeNewswire
7 months ago
Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results
GlobeNewswire
9 months ago
Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
Compare MRKR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MRKR Marker Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.